Antisense-mediated silencing of miR-103 and miR-107 improved insulin sensitivity and glucose homeostasis (Trajkovski et al., 2011) whereas overexpression (predominantly in adipose tissue) was sufficient to cause defects in glucose homeostasis in these mouse models (Naar, 2011; Rottiers and Naar, 2012) Based on these results, RegulusTM developed a GalNAc-conjugated anti-miR-103/107 (RG-125), that was tested for the treatment of nonalcoholic steatohepatitis (NASH) patients who suffered from type 2 diabetes in parallel. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.